all sectors

sector · cluster

Physical health & disease

Eliminate the infectious diseases we already know how to beat.

problems: 2humans affected: 10.6Bcompanies on it: 13capital sources: 7voices: 3

Malaria, TB, and HIV still kill millions every year despite proven interventions. The bottleneck is coverage and delivery, not science. Pair that with the next-gen agenda — broad-spectrum antivirals, CRISPR therapeutics, mRNA platforms — and the floor for civilizational health rises a full order of magnitude.

Problems in this sector

2 ranked

Companies on it

13 mapped →
Modernapublic

mRNA platform company. Pandemic preparedness via rapid vaccine development, plus pipeline in malaria, HIV, and rare disease.

$10.5B

De-extinction and genetic engineering. Biosecurity adjacency via rapid genome editing and cold-chain logistics.

$10.2B
GSKpublic

Global pharma. Manufacturer of RTS, S and R21 malaria vaccines; major HIV and TB portfolios.

$72.0B

HIV franchise leader (Biktarvy, Descovy, lenacapavir as twice-yearly PrEP). Also hep B/C, oncology.

$95.0B

Vaccine alliance funding immunization in low-income countries. Vaccinated over 1B children since 2000.

private · no disclosed cap

Distributes long-lasting insecticidal nets. Consistently top-rated GiveWell charity for cost-effective impact.

private · no disclosed cap

AI-driven drug discovery. Industrializes biology through automated phenotypic screening at scale.

$2.4B

Alphabet-spinoff applying AlphaFold-class ML to drug design. Deals with Novartis and Eli Lilly.

private · no disclosed cap
Altos Labsprivate

Cellular rejuvenation via partial reprogramming. $3B at founding with Shinya Yamanaka on scientific board.

$3.0B

Alphabet company for aging biology. Research partnership with AbbVie; long-horizon mandate rare in pharma.

private · no disclosed cap

Cellular reprogramming, autophagy, and plasma-exchange therapeutics. Seed-funded by Sam Altman at $180M.

private · no disclosed cap
NewLimitprivate

Partial reprogramming for aging, started by Blake Byers, Jacob Kimmel, and Brian Armstrong.

private · no disclosed cap

Capital on it

7 allocators →

Further reading